Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Burger, Jan A, Keating, Michael J, Wierda, William G, Hartmann, Elena, Hoellenriegel, Julia, Rosin, Nathalie Y, de Weerdt, Iris, Jeyakumar, Ghayathri, Ferrajoli, Alessandra, Cardenas-Turanzas, MarylouТом:
15
Мова:
english
Журнал:
The Lancet Oncology
DOI:
10.1016/S1470-2045(14)70335-3
Date:
September, 2014
Файл:
PDF, 555 KB
english, 2014